• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$1.00 -$0.02 (-1.96%)

REAL-TIME: Last trade at

Idera Pharmaceuticals, Inc.

NASDAQ:IDRA

Jump to this page for:

Related Resources

Idera Pharmaceuticals Reports First Quarter 2012 Financial Results

5/9/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals reports Q1 EPS (25c), 1 estimate (26c)

5/9/2012 by Theflyonthewall.com

Idera Pharmaceuticals Reports First Quarter 2012 Financial Results

5/9/2012 by Business Wire

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis

5/7/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals announces efficacy data for IMO-8400

5/7/2012 by Theflyonthewall.com

Idera Pharmaceuticals, Inc. Reports Dissapointing Results From Phase 2 Clinical Trial of IMO-2055

5/3/2012 by BioSpace

Idera Pharmaceuticals reports top-line results from Phase 2 trial of IMO-2055

5/3/2012 by Theflyonthewall.com

Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models

5/1/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals announces presentation of preclinical IMO-8400 data

5/1/2012 by Theflyonthewall.com

Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models

5/1/2012 by Business Wire

Idera Pharmaceuticals Announces Initiation of Treatment in Phase 2 Clinical Trial of IMO-3100 for Psoriasis

4/17/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals announces initiation of treatment in Phase 2 trial

4/17/2012 by Theflyonthewall.com

Idera Pharmaceuticals Announces Initiation of Treatment in Phase 2 Clinical Trial of IMO-3100 for Psoriasis

4/17/2012 by Business Wire

Idera Pharmaceuticals enters into 10M equity sales agreement with Cowen

4/13/2012 by Theflyonthewall.com

Idera Pharmaceuticals rises 31.6%

3/29/2012 by Theflyonthewall.com

Idera Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference

3/29/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference

3/29/2012 by Business Wire

Idera Pharmaceuticals, Inc. (IDRA) Reports Q4 Loss of $0.35/Share

3/14/2012 by StreetInsider.com

Idera Pharmaceuticals anticipates data from certain studies in Q2

3/14/2012 by Theflyonthewall.com

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results and Provides Pipeline Update

3/14/2012 by Business Wire

Idera Pharmaceuticals reports Q4 EPS (35c), one estimate (21c)

3/14/2012 by Theflyonthewall.com

Idera Pharmaceuticals to Present at Cowen’s 32nd Annual Healthcare Conference

2/28/2012 by StockWatch

Idera Pharmaceuticals to Present at Cowen’s 32nd Annual Healthcare Conference

2/28/2012 by Business Wire

Idera Pharmaceuticals to Present at Cancer Immunotherapy Summit on February 28th

2/27/2012 by Genetic Engineering News

Idera Pharmaceuticals to Present at Cancer Immunotherapy Summit on February 28th

2/27/2012 by Business Wire

Idera Pharmaceuticals Announces Retirement of Dr. James B. Wyngaarden as a Member of the Board of Directors

2/17/2012 by Genetic Engineering News

Idera Pharmaceuticals Announces Retirement of Dr. James B. Wyngaarden as a Member of the Board of Directors

2/17/2012 by Business Wire

CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012

2/6/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals to Present at BIO CEO Conference February 14th, 2012

2/6/2012 by Business Wire

Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva® and Avastin® in Patients with Advanced Non-Small Cell Lung Cancer

1/20/2012 by PharmiWeb.com - UK

Idera Pharmaceuticals announces data from Phase 1B IMO-2055 study

1/20/2012 by Theflyonthewall.com

Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva® and Avastin® in Patients with Advanced Non-Small Cell Lung Cancer

1/20/2012 by Business Wire

Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

1/9/2012 by PharmiWeb.com - UK

Idera announces selection of TLR agonist candidates for evaluation

1/9/2012 by Theflyonthewall.com

Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

1/9/2012 by Business Wire

Idera Pharmaceuticals presents positive data on IMO-4200 preclinical models

12/13/2011 by Theflyonthewall.com

Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8, at the American Society for Hematology Meeting

12/13/2011 by Business Wire

Idera Pharmaceuticals files to sell 8.43M of common stock for holders

12/9/2011 by Theflyonthewall.com

Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis

12/1/2011 by PharmiWeb.com - UK

Idera Pharmaceuticals (IDRA) Receives FDA Approval to Proceed with Phase 2 Trials of IMO-3100

12/1/2011 by StreetInsider.com
See More Articles...